Interaction of Activated Protein C with Serpins

Overview

Journal Biochem J

Specialty Biochemistry

Date 1993 Oct 1

PMID 8216224

Citations 7

Authors

J M Hermans

S R Stone

Affiliations

Soon will be listed here.

Abstract

The inhibition of activated protein C by six different serine protease inhibitors (serpins) that have arginine residues in the P1 position has been investigated. Micromolar concentrations of C1-inhibitor failed to inhibit the enzyme, and it was inhibited only slowly by antithrombin III with an association rate constant (kass.) of 0.15 M-1.s-1. The kass. values for the other serpins tested (protease nexin I, protein C inhibitor, and mutants of alpha 1-antichymotrypsin and alpha 1-antitrypsin with P1 arginine residues) were at least 1000-fold higher, with P1-Arg-alpha 1-antitrypsin (kass. = 7 x 10(4) M-1.s-1) being the most effective inhibitor. The inhibition with these four serpins appeared to be reversible, with inhibition constants in the nanomolar range. The relatively high value of kass. for protease nexin I (5 x 10(3) M-1.s-1) suggested that it may be involved in the control of activated protein C on the surface of platelets where protein nexin I is present at relatively high concentrations. The value of kass. for protease nexin I, protein C inhibitor and antithrombin III showed a bell-shaped dependence on heparin concentration. At optimal concentrations, heparin accelerated the rate of inhibition by protease nexin I, protein C inhibitor and antithrombin III by 44-, 18- and 13-fold respectively. The kinetic constants for the inhibition of thrombin were also determined, and in all cases the serpins were more effective inhibitors of thrombin. Comparison of the sequences of the active-site regions of activated protein C and thrombin suggested that the more hydrophobic active site of thrombin may be more favourable for interactions with serpins.

Citing Articles

Loss of Serpin E2 alters antimicrobial gene expression by microglia but not astrocytes.

Krawczyk M, Godoy M, Vander P, Zhang A, Zhang Y Neurosci Lett. 2023; 811:137354.

PMID: 37348749 PMC: 11473033. DOI: 10.1016/j.neulet.2023.137354.

Protease Nexin-1 in the Cardiovascular System: Wherefore Art Thou?.

Madjene C, Boutigny A, Bouton M, Arocas V, Richard B Front Cardiovasc Med. 2021; 8:652852.

PMID: 33869311 PMC: 8044347. DOI: 10.3389/fcvm.2021.652852.

Interaction of protein C inhibitor with the type II transmembrane serine protease enteropeptidase.

Prohaska T, Wahlmuller F, Furtmuller M, Geiger M PLoS One. 2012; 7(6):e39262.

PMID: 22723979 PMC: 3378520. DOI: 10.1371/journal.pone.0039262.

Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.

Burghaus R, Coboeken K, Gaub T, Kuepfer L, Sensse A, Siegmund H PLoS One. 2011; 6(4):e17626.

PMID: 21526168 PMC: 3081290. DOI: 10.1371/journal.pone.0017626.

Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.

Berg D, Gerlitz B, Shang J, Smith T, Santa P, Richardson M Proc Natl Acad Sci U S A. 2003; 100(8):4423-8.

PMID: 12671072 PMC: 153571. DOI: 10.1073/pnas.0736918100.

References

Huber R, Carrell R . Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry. 1989; 28(23):8951-66. DOI: 10.1021/bi00449a001. View

Ranby M, Bergsdorf N, Nilsson T . Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. Thromb Res. 1982; 27(2):175-83. DOI: 10.1016/0049-3848(82)90197-9. View

Heeb M, Bischoff R, Courtney M, Griffin J . Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358. J Biol Chem. 1990; 265(4):2365-9. View

Sommer J, Meyhack B, Rovelli G, Buergi R, Monard D . Synthesis of glia-derived nexin in yeast. Gene. 1989; 85(2):453-9. DOI: 10.1016/0378-1119(89)90439-3. View

Patston P, Roodi N, Schifferli J, Bischoff R, Courtney M, Schapira M . Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems. J Biol Chem. 1990; 265(18):10786-91. View

Maimone M, Tollefsen D . Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem. 1990; 265(30):18263-71. View

Kuhn L, Griffin J, Fisher C, Greengard J, Bouma B, Espana F . Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. Proc Natl Acad Sci U S A. 1990; 87(21):8506-10. PMC: 54985. DOI: 10.1073/pnas.87.21.8506. View

Longstaff C, Gaffney P . Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry. 1991; 30(4):979-86. DOI: 10.1021/bi00218a014. View

Baumann U, Huber R, Bode W, Grosse D, Lesjak M, LAURELL C . Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7 A resolution and its comparison with other serpins. J Mol Biol. 1991; 218(3):595-606. DOI: 10.1016/0022-2836(91)90704-a. View

10.

Espana F, Estelles A, Griffin J, Aznar J . Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma. Thromb Haemost. 1991; 65(1):46-51. View

11.

Heeb M, Gruber A, Griffin J . Identification of divalent metal ion-dependent inhibition of activated protein C by alpha 2-macroglobulin and alpha 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem. 1991; 266(26):17606-12. View

12.

Evans D, McGrogan M, Scott R, Carrell R . Protease specificity and heparin binding and activation of recombinant protease nexin I. J Biol Chem. 1991; 266(33):22307-12. View

13.

Rovelli G, Stone S, Guidolin A, Sommer J, Monard D . Characterization of the heparin-binding site of glia-derived nexin/protease nexin-1. Biochemistry. 1992; 31(13):3542-9. DOI: 10.1021/bi00128a031. View

14.

Martin P, Robertson W, Turk D, Huber R, Bode W, EDWARDS B . The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. J Biol Chem. 1992; 267(11):7911-20. View

15.

Pratt C, Church F . Heparin binding to protein C inhibitor. J Biol Chem. 1992; 267(13):8789-94. View

16.

Pratt C, Whinna H, Church F . A comparison of three heparin-binding serine proteinase inhibitors. J Biol Chem. 1992; 267(13):8795-801. View

17.

Stubbs M, Oschkinat H, Mayr I, Huber R, Angliker H, Stone S . The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur J Biochem. 1992; 206(1):187-95. DOI: 10.1111/j.1432-1033.1992.tb16916.x. View

18.

Bode W, Turk D, Karshikov A . The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1992; 1(4):426-71. PMC: 2142221. DOI: 10.1002/pro.5560010402. View

19.

Laurell M, Christensson A, Abrahamsson P, Stenflo J, Lilja H . Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J Clin Invest. 1992; 89(4):1094-101. PMC: 442965. DOI: 10.1172/JCI115689. View

20.

Danielsson A, BJORK I . Mechanism of inactivation of trypsin by antithrombin. Biochem J. 1982; 207(1):21-8. PMC: 1153818. DOI: 10.1042/bj2070021. View